PCV68 POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY TO OPTIMIZE STATIN THERAPY

Saved in:
Bibliographic Details
Published inValue in health Vol. 13; no. 7; p. A353
Main Authors Burgers, LT, Redekop, WK, Severens, JL
Format Journal Article
LanguageEnglish
Published Elsevier Inc 2010
Subjects
Internal Medicine
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/S1098-3015(11)72411-1